| USGOV-DEPARTMENT-OF-DEFENSE |
USGOV-DEPARTMENT-OF-DEFENSE |
95%
|
USAspending awards from Department of Defense: $145,145 across 5 awards. SPE7MX25F251K 8511644365!MISCELLANEOUS; SPE7M125F2316 8511450976!MISCELLANEOUS; SPE7M125F1399 8511273757!MISCELLANEOUS | Qwen … |
| CUNY |
CUNY |
92%
|
65% of the revenues earned for the fiscal year ended September 30, 2023 was derived from the COVID-19 testing contract with CUNY that terminated during June 2023. |
| THERAPEUTIC-DNA-PRODUCTION-SERVICES-SEGMENT |
THERAPEUTIC-DNA-PRODUCTION-SERVICES-SEGMENT |
90%
|
The Company's revenues earned from sale of products and services for the three months ended March 31, 2026 was 86 % from one customer within the Therapeutic DNA Production Services segment. |
| DNA-TAGGING-AND-SECURITY-PRODUCTS-AND-SERVICES-S |
DNA-TAGGING-AND-SECURITY-PRODUCTS-AND-SERVICES-S |
85%
|
The Company's revenue earned from the sale of products and services for the six months ended March 31, 2025 was 27 % and 12 % from two customers within the DNA Tagging and Security Products and Servi… |
| THERAPEUTIC-DNA-PRODUCTION-SERVICES |
THERAPEUTIC-DNA-PRODUCTION-SERVICES |
85%
|
The Company's revenues earned from sales of products and services for the three months ended March 31, 2025 included an aggregate of 44 % and 11 % from two customers within the Therapeutic DNA Produc… |
| MDX-TESTING-SERVICES |
MDX-TESTING-SERVICES |
80%
|
The Company's revenue earned from the sale of products and services for the six months ended March 31, 2025 was 27 % and 12 % from two customers within the DNA Tagging and Security Products and Servi… |
| FLGT |
Fulgent Genetics, Inc. |
72%
|
Reciprocal relationship from FLGT graph: Reciprocal relationship from BNBX graph: ices for the fiscal year ended September 30, 2024 includes 26% and 17% from two customers within our MDx Testing Serv… |
| FLGT |
Fulgent Genetics, Inc. |
72%
|
ices for the fiscal year ended September 30, 2024 includes 26% and 17% from two customers within our MDx Testing Services and Therapeutic DNA Production segments, respectively. Our revenues earned fr… |
| IEHC |
IEH Corporation |
72%
|
Reciprocal relationship from IEHC graph: Reciprocal relationship from BNBX graph: Reciprocal relationship from IEHC graph: Reciprocal relationship from BNBX graph: Reciprocal relationship from IEHC g… |
| IEHC |
IEH Corporation |
72%
|
t our ability to maintain production of our products and achieve profitability. Unforeseen discontinuation or unavailability of certain components, such as enzymes (e.g., DNAP and RNAP), nucleotides,… |
| MRK |
Merck & Co., Inc. |
72%
|
ices for the fiscal year ended September 30, 2024 includes 26% and 17% from two customers within our MDx Testing Services and Therapeutic DNA Production segments, respectively. Our revenues earned fr… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from BNBX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BNBX graph: Reciprocal relationship from MRK grap… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
ices for the fiscal year ended September 30, 2024 includes 26% and 17% from two customers within our MDx Testing Services and Therapeutic DNA Production segments, respectively. Our revenues earned fr… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from BNBX graph: ices for the fiscal year ended September 30, 2024 includes 26% and 17% from two customers within our MDx Testing Serv… |
| NVSEF |
Novartis AG |
72%
|
t our ability to maintain production of our products and achieve profitability. Unforeseen discontinuation or unavailability of certain components, such as enzymes (e.g., DNAP and RNAP), nucleotides,… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNBX graph: t our ability to maintain production of our products and achieve profitability. Unforeseen discontinuation or unavai… |
| INTEGRATED-DNA-TECHNOLOGIES-INC |
INTEGRATED-DNA-TECHNOLOGIES-INC |
62%
|
t our ability to maintain production of our products and achieve profitability. Unforeseen discontinuation or unavailability of certain components, such as enzymes (e.g., DNAP and RNAP), nucleotides,… |
| PLC-ZIOPHARM-ONCOLOGY-INC-MAXCYTE-INC-TOUCHLIGHT |
PLC-ZIOPHARM-ONCOLOGY-INC-MAXCYTE-INC-TOUCHLIGHT |
62%
|
t our ability to maintain production of our products and achieve profitability. Unforeseen discontinuation or unavailability of certain components, such as enzymes (e.g., DNAP and RNAP), nucleotides,… |
| PRECIGEN-INC-ALDEVRON-LLC-COBRA-BIOLOGICS-LIMITE |
PRECIGEN-INC-ALDEVRON-LLC-COBRA-BIOLOGICS-LIMITE |
62%
|
t our ability to maintain production of our products and achieve profitability. Unforeseen discontinuation or unavailability of certain components, such as enzymes (e.g., DNAP and RNAP), nucleotides,… |
